Novartis以12B美元购买抗体, 强化其罕见疾病和RNA治疗计划。 Novartis to buy Avidity for $12B, boosting its rare disease and RNA therapy programs.

Novartis AG同意在120亿美元的现金交易中收购Avidity Biosciences, 与Avidity股东每股获得72美元, 比最近的关闭价格高46%的溢价。 Novartis AG has agreed to acquire Avidity Biosciences in a $12 billion cash deal, with Avidity shareholders receiving $72 per share, a 46% premium over its recent closing price. 此次收购正在等待监管部门的批准，并将 Avidity 的心脏病学项目分拆为一家名为 SpinCo 的新公司，将扩大诺华的罕见病产品线，包括杜氏病、强直性和面肩肱型肌营养不良症的后期项目。 The acquisition, pending regulatory approval and the spin-off of Avidity’s cardiology programs into a new company called SpinCo, will expand Novartis’s rare disease pipeline, including late-stage programs for Duchenne, myotonic, and facioscapulohumeral muscular dystrophies. 该交易包括Avidity的抗体寡核酸结合平台,该平台可实现向RNA治疗. The deal includes Avidity’s Antibody Oligonucleotide Conjugate platform, which enables targeted RNA therapies. 预计将于2026年初关闭。 Closing is expected in early 2026.